Beneficial Effects of Mammalian Target of Rapamycin Inhibition on Left Ventricular Remodeling After Myocardial Infarction  by Buss, Sebastian J. et al.
I
m
v
m
F
m
C
D
G
S
a
(
t
m
c
a
Journal of the American College of Cardiology Vol. 54, No. 25, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PPRE-CLINICAL RESEARCH
Beneficial Effects of Mammalian
Target of Rapamycin Inhibition on Left
Ventricular Remodeling After Myocardial Infarction
Sebastian J. Buss, MD,* Sebastian Muenz, MD,* Johannes H. Riffel, MD,* Pratima Malekar, PHD,*
Marco Hagenmueller, PHD,* Celine S. Weiss, MD,* Florian Bea, MD,* Raffi Bekeredjian, MD,*
Martina Schinke-Braun, PHD,† Seigo Izumo, MD, PHD,† Hugo A. Katus, MD,*
Stefan E. Hardt, MD*
Heidelberg, Germany; and Cambridge, Massachusetts
Objectives The extent of adverse myocardial remodeling contributes essentially to the prognosis after myocardial infarction
(MI). In this study we investigated whether inhibition of “mammalian target of rapamycin” (mTOR) attenuates
left ventricular (LV) remodeling after MI.
Background Therapeutic strategies to inhibit remodeling are currently limited to inhibition of neurohumoral activation. The
mTOR-dependent signaling mechanisms are centrally involved in remodeling processes and provide new thera-
peutic opportunities.
Methods Everolimus (RAD) treatment was initiated on the day after or 3 days after induction of myocardial infarction (MI)
in rats.
Results After 28 days, RAD-treated animals had reduced post-MI remodeling, with improved LV function and smaller LV
end-diastolic diameters (8.9  0.3 mm vs. 11.4  0.2 mm, p  0.05), end-diastolic volumes (304  30 l vs.
414  16 l, p  0.05), and cardiac myocyte size (40% vs. vehicle, p  0.05). Infarct size was significantly
reduced compared with vehicle-treated animals. The mTOR inhibition increased autophagy and concomitantly
decreased proteasome activity in the border zone of the infarcted myocardium. Measurement of autophagic flux
demonstrated that RAD did not decrease autophagosome clearance. When RAD treatment was initiated 3 days
after MI, adverse remodeling was still attenuated and increased autophagy was still present. Sustained
improvement of LV function was observed 3 months after MI, even when RAD treatment was discontinued after
1 month.
Conclusions Inhibition of mTOR is a potential therapeutic strategy to limit infarct size and to attenuate adverse LV remodel-
ing after MI. (J Am Coll Cardiol 2009;54:2435–46) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.031i
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rschemic heart disease is one of the leading causes of
orbidity and mortality worldwide (1,2). An increase in
entricular volume is a primary predictor of mortality after
yocardial infarction (MI) (3). Thus, one of the most
rom the *Department of Cardiology, University of Heidelberg, Heidelberg, Ger-
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rimmke-Stiftung (12/04), and by a research grant from Novartis to Dr. Hardt. Drs.
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WO2006124739, EP1888062). At the time of publication Dr. Izumo was not available
o sign the relationship with industry form signed by all the other authors on the
anuscript. It is confirmed that he was an employee of Novartis at the time the study was
onducted and the manuscript prepared.f
Manuscript received April 30, 2009; revised manuscript received August 18, 2009,
ccepted August 24, 2009.mportant factors for improving the prognosis after MI is
he attenuation of adverse myocardial remodeling (4,5). Due
o improvement of therapeutic strategies after MI, mortality
ecreased significantly in the past decades. Consecutively,
here is also an increasing number of patients whose
rognosis depends on optimal treatment after MI. Despite
he widespread use of angiotensin-converting enzyme in-
ibitors, beta-blockers, and aldosterone-antagonists, the
ncidence of heart failure as the end-stage of left ventricular
LV) remodeling still remains high.
Underlying mechanisms of remodeling are manifold, in-
luding activation of physical and neurohumoral processes as
ell as activation of growth factors and the protein translation
achinery (6,7). Despite its well-known role in the myocardial
emodeling process, protein synthesis has not been investigated
or its potential to influence the remodeling process. One
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mTOR Inhibition in Myocardial Infarction December 15/22, 2009:2435–46important molecule related to pro-
tein synthesis is the “mammalian
target of rapamycin” (mTOR),
which is mainly activated via the
Akt/PI3K pathway. This signaling
mechanism is centrally involved in
physiological hypertrophy but also
takes part in pathological remod-
eling of the heart (8–10). The
mTOR inhibitors such as rapamy-
cin or everolimus (RAD) have an
inhibitory effect on protein synthe-
sis via direct inhibition of mTOR.
Due to its immunosuppressant ac-
tions, mTOR inhibitors thus far
have mainly been used in trans-
plantation medicine. However,
they are also being used as prolif-
eration inhibitors for coating drug-
eluting stents to reduce restenosis
after coronary angioplasty. Siroli-
mus is even effective to prevent
estenosis when given orally (11). In the context of LV
ypertrophy, recent studies indicate that rapamycin has an
nhibitory effect on development of LV hypertrophy in vivo
8,10). In this study, we tested the hypothesis of whether
reatment with mTOR inhibitors can prevent adverse LV
emodeling after MI.
ethods
he investigation conforms to the guide for the care and use
f laboratory animals published by the U.S. National Insti-
utes of Health (NIH Publication No. 85-23, revised 1996)
nd was approved by the authorities of the Regierungsprä-
idium Karlsruhe, Germany.
tudy design. After surgery, animals were randomized for
reatment with RAD (3.0 mg/kg/day) or vehicle by oral
avage starting after recovery from surgery. The RAD
reatment with a dose of 3.0 mg/kg/day has been established
o be efficacious and well-tolerated in previous studies
12,13). For basic characterization, including echocardiog-
aphy and hemodynamic measurements, animals were killed
8 days after MI. For protein analysis, a subgroup of
nimals was killed at days 1, 3, 14, and 28 after surgery. In
ddition, we investigated the effect of delayed treatment
ith RAD (3.0 mg/kg/day) starting 3 days after induction
f MI. In an additional experimental series, we examined
hether 1-month treatment with RAD (starting on day 1
fter MI) would have sustained effects on LV function after
months. For killing, anesthesia was induced by intraperi-
oneal injection of ketamine (70 mg/kg) and xylazine (2 to
mg/kg), and echocardiographic and invasive measure-
ents were performed. The heart was then arrested in
iastole by injection of saturated potassium chloride solu-
Abbreviations
and Acronyms
AMC  7-amino-4-
methylcoumarin
EDD  end-diastolic
diameter
ESD  end-systolic
diameter
LV  left ventricle/
ventricular
MDC 
monodansylcadaverine
MI  myocardial infarction
mTOR  mammalian target
of rapamycin
NFB  nuclear factor-
kappa B
RAD  everolimus
TTC  triphenyl tetrazolium
chlorideion. After dissecting the LV, myocardial samples from iifferent regions of the LV (infarcted area, border zone, and
emote area) were snap frozen for biochemical measure-
ents or fixed in formalin for further histological
valuation.
I. For the MI model we used male Wistar rats with a
eight of 200 g (Charles River Laboratories, Sulzfeld,
ermany). Animals were anesthetized by IP injection of
etamine (70 mg/kg) and xylazine (2 to 5 mg/kg). After
rotracheal intubation and ventilation, the thorax was
pened left parasternally, and MI was induced by ligating
he left anterior descending coronary artery just below the
eft atrial appendage. The quality of the infarction was
onfirmed visually by the change of the color of the
yocardium.
chocardiography. Transthoracic echocardiography was
erformed in a modified setting as previously described in
etail (14). Studies were recorded with a dynamic focused
0-MHz probe with an ATL 5000 echocardiography ma-
hine. The M-mode measurements of LV dimensions were
veraged from more than 3 cycles. The investigator who
onducted the echocardiography was blinded for the treat-
ent status.
V pressure–volume measurements. For the invasive as-
essment of pressure–volume relationships, rats were anes-
hetized as described in the preceding text. The LV was
atheterized retrogradely via the right carotid artery with a
.0-F impedance-micromanometer catheter (Millar Instru-
ents, Inc., Houston, Texas). The raw conductance vol-
mes were corrected for parallel conductance by the hyper-
onic saline dilution method. For absolute volume
easurements, the catheter was calibrated with known
olumes of heparin-treated rat blood. Data were recorded
ith a sampling rate of 1,000 Hz with the Chart software
ADInstruments, Colorado Springs, Colorado). For subse-
uent analysis of pressure-volume loops PVAN software
Millar Instruments, Inc.) was used.
athology. Histological studies were conducted with
ormalin-fixed, paraffin-embedded hearts from animals of
ll groups. Cross sections of the LV obtained midway
etween base and apex were stained with hematoxylin/
osin, and myocyte size was measured with the ImageJ
oftware (ImageJ, NIH, Bethesda, Maryland). To assess
acrophage infiltration of the infarcted area, immunohis-
ochemistry was performed with ED1 antibody. Infarct size
8 days after MI was assessed by triphenyl tetrazolium
hloride (TTC) staining and by histology with Masson’s
richrome staining. The tissue slices were photographed,
nd the infarcted area was calculated as percentage of the
hole LV with ImageJ software (ImageJ).
utophagic flux. We investigated autophagic flux in vivo,
ccording to the previously described method by Iwai-Kanai et
l. (15). After surgery, the animals were randomized for
reatment with RAD (3.0 mg/kg/day) or vehicle. Animals
ere killed 72 h after infarction. Four hours before the animals
ere killed, we injected chloroquine (10 mg/kg IP), which
nhibits lysosomal activity. The administration of monodan-
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December 15/22, 2009:2435–46 mTOR Inhibition in Myocardial Infarctionylcadaverine (MDC) (1.5 mg/kg) was done via IP injection
h before the animals were killed. MDC is known to label
cidic endosomes, lysosomes, and autophagosomes (16,17).
ne hour after MDC injection, animals were killed and
ardiac tissue was harvested immediately. The tissues were
xed in 10% formalin for preparation of paraffin-embedded
ections and examined for cardiac autophagy under a fluores-
ence microscope.
estern blot analysis. For further biochemical analysis,
nimals were killed 1, 14, or 28 days after MI. Analysis of
Figure 1 mTOR Inhibition Attenuates Myocardial Remodeling A
(A) Transthoracic echocardiographic M-Mode images recorded from the parasterna
vehicle-, and everolimus (RAD)-treated (3.0 mg/kg/day) animals after 28 days. (B)
as compared with vehicle. (C) End-diastolic diameter (EDD) and (D) end-systolic d
images. The EDD and ESD were significantly reduced in RAD-treated animals (3.0
n  6, vehicle n  14, RAD n  14. MI  myocardial infarction; mTOR  mamma
Hemodynamic Parameters of Vehicleand RAD-Treated Animals 28 Days After MyocarTable 1 Hemodynamic Paramet rs of Vehicland RAD-Treated Animals 28 Days
Sham (n 
Heart rate (beats/min) 411 10
End-systolic volume (l) 142 21
End-diastolic volume (l) 304 23
End-systolic pressure (mm Hg) 147 17
End-diastolic pressure (mm Hg) 3.2 0.6
Stroke volume (l) 183 17
Ejection fraction (%) 58 6
dP/dt max (mm Hg/s) 11,308 990
dP/dt min (mm Hg/s) 11,013 1,0
Tauw (ms) 8.6 0.3
Results are presented as average  SEM. *p  0.05 versus sham; †p
RAD  everolimus.AD effects was performed with RAD treatment starting 1
nd 3 days after MI. LV protein lysates (100 g) were
repared from the LV tissue of the remote area. Western
lot analysis of lysates of the rat hearts were performed as
escribed previously (18). Protein-loading was confirmed by
oomassie blue staining. Primary antibodies used were
EBP-1 (Santa Cruz Biotechnology, Inc., Santa Cruz,
alifornia), phospho 4E-BP1 (Cell Signaling Technology,
nc., Beverly, Massachusetts), p70/S6 (Santa Cruz Biotech-
ology, Inc.), phospho p70/S6 (Cell Signaling Technology
I
t axis on the level of the papillary muscles of the left ventricle (LV) in sham-,
on fraction (EF) was significantly higher in the RAD-treatment group after 28 days
r (ESD) of the LV estimated from transthoracic echocardiographic M-Mode
/day) after 28 days. *p  0.05 versus sham; #p  0.05 versus vehicle. Sham
rget of rapamycin.
nfarction
Myocardial Infarction
Vehicle (n  15) RAD 3.0 (n  9)
379 15 357 26
349 14* 215 30†
414 16* 304 30†
120 5* 120 6
9.6 0.6* 4.6 0.7†
87 7* 105 9
20 1* 35 4†
6,982 597* 8,086 743
5,305 364* 5,345 410
14.7 0.7* 13.8 1.3
5 versus vehicle.fter M
l shor
Ejecti
iamete
mg/kg
lian tadial Ie
After
5)
94
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mTOR Inhibition in Myocardial Infarction December 15/22, 2009:2435–46Figure 2 Representative Pressure-Volume Loops During Steady-State
Conditions in Sham-, Vehicle-, and RAD-Treated Rats 28 Days After MI
A significant rightward shift of the pressure volume loops is observed in the vehicle-treated animals,
which can be reduced (“leftwarded”) by treatment with RAD 3.0 mg/kg/day. RVU  relative volume unit; other abbreviations as in Figure 1.Vehicle
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Figure 3 Effects of RAD Treatment on Infarct Size and Myocardial Hypertrophy
(A) Quantitative measurement of infarct size by triphenyl tetrazolium chloride (TTC) staining. Infarct size was significantly smaller in RAD-treated animals as compared
with vehicle-treated animals 28 days after MI. (B) Representative examples of Masson’s trichrome staining of infarcted hearts. Smaller infarct size was confirmed by his-
tology in the RAD-treatment group. (C) The increased ratio of heart weight (HW) to tibia length (TL) in vehicle-treated MI-animals was significantly reduced after RAD treat-
ment. *p  0.05 versus sham; #p  0.05 versus vehicle. Abbreviations as in Figure 1.
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December 15/22, 2009:2435–46 mTOR Inhibition in Myocardial Infarctionnc.), ribosomal S6 (Santa Cruz Biotechnology, Inc.), phos-
ho ribosomal S6 (Cell Signaling Technology, Inc.), LC3B
Cell Signaling Technology, Inc.), ubiquitin (P4D1, Cell
ignaling Technology, Inc.), and p65 (Cell Signaling Tech-
ology Inc.).
roteasome activity assay. The commercially available
Proteasome Activity Assay Kit” (Millipore, Bedford, Mas-
achusetts) was used for assaying the proteasome activity
hat recognizes the substrate LLVY (19). The assay is
ainly based on the detection of the fluorophore 7-amino-
-methylcoumarin (AMC) after cleavage from the labeled
ubstrate LLVY-AMC. The free AMC fluorescence was
uantified with a 380/460 nm filter set in a fluorometer.
ene expression. Real-time polymerase chain reaction was
erformed with the TaqMan assay. Structural modifications
f the dNTPs in the sense of a locked nucleic acid allow
elatively high annealing temperatures. During the elonga-
ion period the deoxyribonucleic acid polymerase destroys
he TaqMan-probe through its 5=-exonnuclease activity and
eparates the quencher from the fluorescence molecule,
llowing the fluorescence signal to be registered.
lectrophoretic mobility shift assay for nuclear factor-
appa B (NFB). Activity of NFB was assessed with
lectrophoretic mobility shift assay as described previously
20). In brief, tissue from the border zone of the infarction
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Figure 4 Effects of RAD Treatment on Cardiac Myocyte Size an
(A) Exemplary hematoxylin eosin stainings of a section of the remote area of the
ment of the myocyte size 28 days after MI. Myocyte size was significantly smaller
n  5, RAD n  13. (C) Gene expression of atrial natriuretic factor (ANF) normaliz
but not in the RAD-treatment group. *p  0.05 versus sham; #p  0.05 versus vas homogenized in 400 l of hypotonic buffer. Nuclear
ractions were obtained and resuspended in 50 l ice-cold
uffer C. Nuclear extracts (10 g each) were incubated with
abe led ol igonuc leot ide probes and 2 g of
oly(deoxyinosine-deoxycytidine)-poly(deoxyinosine-
eoxycytidine) in 20 l of binding buffer. The sequences of
he oligonucleotides for NFB were used (Santa Cruz
iotechnology). Binding reactions were resolved on a 4%
ative polyacrylamide gel and exposed to X-ray film for 12
o 24 h.
tatistics. The results are expressed as mean  SEM.
tatistical analysis was performed with the Graph-Pad
rism Software Package (GraphPad, Inc., San Diego,
alifornia). Differences between groups were tested by
-way analysis of variance with post hoc comparisons by
unnett’s post hoc test and paired or unpaired Student t test
here appropriate. The differences between groups in the
ong-term observation were tested by 2-way analysis of
ariance.
esults
TOR inhibition attenuates myocardial remodeling after
I. After 1 month, echocardiographic and invasive hemo-
ynamic measurements demonstrated a reduction of LV
ystolic and diastolic function in vehicle-treated animals as
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ham, vehicle, and RAD-treated animals after 28 days. (B) Quantitative measure-
-treated animals as compared with vehicle-treated animals. Sham n  5, vehicle
the house-keeping gene HPRT was significantly increased in vehicle MI-animals
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mTOR Inhibition in Myocardial Infarction December 15/22, 2009:2435–46ompared with sham-operated animals (Table 1). The
AD treatment (3.0 mg/kg/day) led to an attenuation of
ardiac remodeling. Ejection fraction as determined by
chocardiography was significantly reduced in the vehicle
roup (37  2% vs. 77  1%), whereas in the RAD group,
jection fraction was higher as compared with the vehicle
roup (63  2%) (Figs. 1A and 1B). LV end-diastolic
iameter (EDD) and end-systolic diameter (ESD) dimen-
ions were markedly enlarged in vehicle-treated animals
EDD 11.4  0.2 mm, and ESD 9.7  0.2 mm) as
ompared with RAD-treated animals (EDD 8.9  0.3 mm,
nd ESD 6.4 0.3 mm) (Figs. 1C and 1D). Hemodynamic
easurements confirmed improvement of systolic and dia-
tolic dysfunction in the RAD group as compared with
ehicle-treated rats with MI (Table 1, Fig. 2). Ejection
raction as assessed by pressure-volume measurements was
5 4% in the RAD group and 20 1% in vehicle-treated
nimals (p 0.05). Compared with vehicle-treated animals,
AD treatment caused a substantial leftward shift of the
Figure 5 Protein Levels and Phosphorylation Levels of mTOR-Re
(A) Western blot analysis revealed a significant decrease of phosphorylation of 4E
S6K after MI; p70/S6K, 1 of the main downstream targets of mTOR—which medi
tration of RAD after MI. (C) Phospho ribosomal S6K is significantly reduced by mT
vehicle; other abbreviations as in Figure 1.V pressure-volume curves (Fig. 2). In addition, RAD
reatment reduced the increase in LV end-diastolic volume
304 30 l vs. 414  16 l for RAD- and vehicle-treated
ats, respectively, p  0.05) (Table 1).
ffects of RAD on infarct size and myocardial hypertro-
hy. The RAD treatment (3 mg/kg/day) after induction of
I led to a significant decrease of infarct size as compared with
ehicle treatment as assessed by TTC staining (Fig. 3A),
hereas area at risk was similar to vehicle-treated animals.
istological examination also showed a reduction of infarct
ize (30  2% vs. 21  4%) (Fig. 3B). By this time the
ncrease in the ratio of LV weight to tibia length observed
n vehicle-treated animals with MI was significantly blunted
n the RAD-treatment group (Fig. 3C). Next, we evaluated
he effect of RAD on cardiac myocyte size in the vital area
emote from the infarction. After 4 weeks, there was a
ignificant increase in cardiac myocyte size in the MI group
s compared with sham-operated animals, whereas myo-
ytes from MI animals treated with RAD were approxi-
Regulators of Protein Synthesis
Thr 70) after administration of RAD after MI. (B) Protein levels of phospho-p70/
llular growth—displayed a significant decrease of phosphorylation after adminis-
ibition. Coomassie blue staining confirms similar loading of protein. Veh lated
-BP1 (
ates ce
OR-inh
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Figure 6 Protein Degradation Mechanisms Are Regulated by mTOR After MI
(A) LC3, a marker of autophagy, is up-regulated in the border zone 3 days after MI in RAD-treated animals. (B and C) Detection of autophagosomes in vivo by monodansylca-
daverine (MDC) 3 days after MI in vehicle (Veh)- and RAD-treated animals (B). Activity of LC3 corresponded to autophagous flux assessed by MDC (C). (D and E) Concomitant
down-regulation of the ubiquitin proteasome system is observed. (F) Electrophoretic mobility shift assay blot for nuclear factor-kappa B (NFB), demonstrating a reduced
activity in MI animals after RAD-treatment. (G) Densitometric quantification of NFB clearly demonstrates the significant reduction of NFB in the border zone of the
infarction. (H) Western blot of the p65 subunit also showed significant reduction due to treatment with RAD. (I) In the border zone of the infarction, a reduced macro-
phage invasion was observed. #p  0.05 versus Veh. Cq  chloroquine; RFU  relative fluorescence units; other abbreviations as in Figure 1.
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mTOR Inhibition in Myocardial Infarction December 15/22, 2009:2435–46ately 40% smaller as compared with the untreated MI
roup (Figs. 4A and 4B). Gene expression of atrial natri-
retic factor was significantly increased in vehicle-treated
I animals, whereas RAD-treated MI animals displayed
o significant difference compared with sham-operated
nimals (Fig. 4C).
nhibition of protein synthesis through RAD. As previ-
usly described (8,10), mTOR inhibitors such as RAD
lock the protein kinase mTOR (especially TORC1, the
TOR-raptor complex), which phosphorylates molecules
nvolved in the regulation of protein synthesis such as S6
inase and 4EBP-1 (Fig. 5). The 4EBP-1, which negatively
egulates protein synthesis, was less phosphorylated in the
AD group, indicating increased restrain on protein syn-
hesis (Fig. 5A). Interestingly, in vehicle-treated animals
ith MI that were killed 1, 14, and 28 days after MI, we
ound a significant increase in phosphorylation of p70/S6-
inase, indicating activation of protein translation after MI
Fig. 5B). However, in RAD-treated animals with MI,
hospho p70/S6-kinase as well as its downstream target
ibosomal S6 were less phosphorylated leading into inacti-
ation of these molecules (Fig. 5C). Total levels of p70/S6K
nd ribosomal S6 remained unchanged (Figs. 5B and 5C).
TOR regulates autophagy and proteasomal degrada-
ion and attenuates inflammatory response after MI. Be-
ause mTOR is one of the essential regulators of autophagy,
Figure 7 Morphology and Echocardiography After Initiation of R
(A) The increased HW/TL ratio in vehicle-treated MI-animals was significantly reduced
surement of the myocyte size 28 days after MI. Myocyte size was significantly smaller
echocardiography. (C) The EF was significantly higher in the RAD-treatment group a
a significant reduction due to RAD treatment compared with vehicle. #p  0.05 veprocess that has recently been associated with myocardial
schemia, we investigated whether inhibition of mTOR led
o increased autophagy. LC3, a marker of autophagy, was
ignificantly increased in the border zone of the infarction in
AD-treated animals 3 days after MI (Fig. 6A). To
xamine whether increase of LC3 was due to increased
utophagosome formation or impairment of lysosomal fu-
ion, we additionally measured autophagic flux in vivo with
DC as a marker of autophagosomes 3 days after MI
Fig. 6B). Fluorescence microscopy revealed an increase of
utophagosomes in RAD-treated animals and a further
ncrease after administration of chloroquine, which indi-
ates that RAD does not lead to decreased clearance of
utophagosomes. In concordance with these findings, in-
reased activity of LC3 was found in the same experimental
etting with chloroquine (Fig. 6C). Interestingly, with RAD
reatment, decreased activity of the ubiquitin-proteasome
ystem was observed, demonstrated by a decrease of ubiqui-
inated proteins (Fig. 6D) and a decrease of proteasomal
ctivity (Fig. 6E). Next, we investigated whether protea-
ome inhibition results in decreased NFB activity. NFB
s known to be pro-inflammatory with important impact on
ardiovascular remodeling (21) and was found to have a
ivotal role in infarct size (22). Treatment with RAD led to
significant reduction of NFB in the border zone of MI as
ompared with vehicle-treated animals (Figs. 6F and 6G).
reatment 3 Days After MI
AD treatment (3.0 mg/kg/day) starting 3 days after infarction. (B) Quantitative mea-
-treated animals as compared with vehicle-treated animals. (C to E) Transthoracic
8 days as compared with vehicle. (D and E) The EDD and ESD of the LV showed
ehicle. Abbreviations as in Figures 1 and 3.AD T
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December 15/22, 2009:2435–46 mTOR Inhibition in Myocardial Infarctionmmunoblotting of the p65 subunit also showed a clear
eduction (Fig. 6H), in concordance with these findings.
acrophage invasion into the infarcted area, representing
n essential step of inflammatory response, was also dimin-
shed 72 h after MI (Fig. 6I). These data suggest that—
esides inhibition of protein synthesis—increase of autoph-
gy, proteasome inhibition, and reduced inflammation
ontribute to the beneficial effects of RAD after MI.
iming of mTOR inhibition. Because patients in the
linical setting frequently present in subacute stages of MI,
e investigated whether RAD favorably affects myocardial
emodeling in the later phase of MI. Therefore, we initiated
AD treatment (3.0 mg/kg/day) or vehicle treatment 3 days
fter MI. Infarct size was not significantly altered in the
ate-treatment RAD group as compared with the vehicle-
reated group (37% vs. 40%). Interestingly, significant at-
enuation of myocardial remodeling was still observed in
his RAD group, although the beneficial effect was smaller
s compared with the earlier administration, starting within
day after MI (Figs. 7A and 7B). In addition, a reduction
n relative myocyte size by 25% as compared with vehicle-
reated animals was still observed (Fig. 7B). Rats were also
haracterized by transthoracic echocardiography after a
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Figure 8 Autophagy and NFB Activation 28 Days After MI Wit
(A) LC3, a marker of autophagy, is still up-regulated in the remote area 28 days a
tant down-regulation of the ubiquitin proteasome system is still observed. (C and
MI animals with RAD treatment initiated 3 days after MI in the remote area of the
Abbreviations as in Figures 1 and 6.reatment period of 28 days (Figs. 7C to 7E). Again, uignificant attenuation of myocardial remodeling was clearly
isible. Increase of LC3 and a decrease of ubiquitinated
roteins as well as reduced NFB activity were still present in
he remote area 28 days after MI in the early-treatment group
s well as in the late-treatment group (Figs. 8A to 8C).
We further investigated whether RAD treatment exerts
eneficial effects when given only temporarily (treatment
tarted on day 1 after MI and continued for 1 month). In
nimals that were killed 3 months after MI (i.e., 2 months
fter discontinuing RAD treatment), the improvement of
V function was still clearly detectable (Fig. 9). Thus, the
TOR inhibitor RAD exerts long-term beneficial effects
n adverse remodeling.
iscussion
he main finding of this study is that targeting the
RAP/mTOR pathway systemically can prevent adverse
V remodeling and limit infarct size after MI. Of note,
edication in this study was initiated on the day after
nduction of MI, thus closely resembling a frequent clinical
ituation. When RAD was given 3 days after MI, infarct
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linically relevant dose, RAD effectively attenuated
nfarction-induced remodeling.
olecular mechanisms of mTOR-inhibition leading to
educed myocardial remodeling. It is known that mTOR
lays a key role in regulating cellular growth and develop-
ent (23,24). An inhibitory effect of rapamycin on devel-
pment of LV hypertrophy in the setting of aortic banding
n mice has been demonstrated previously (8,10). Khan et al.
25) have recently reported protective effects of rapamycin in
he context of ischemia/reperfusion. In this setting, the
nfarct size reduction was mainly attributed to opening of
itochondrial adenosine triphosphate channels. In contrast,
is at al. (26) demonstrated that administration of mTOR
nhibitors before onset of ischemia diminishes the cardio-
rotective effect of ischemic pre-conditioning. However,
hese findings were derived from a Langendorff model of
schemia/reperfusion. In the present study we examined the
ole of mTOR inhibition in an in vivo model, which allows
nvestigation of the long-term course and chronic remodel-
ng effects. In contrast to Kis, we applied mTOR inhibitors
fter myocardial ischemia, as is the case in a clinical setting.
P70/S6K is one of the main downstream targets of
TOR. Interestingly, p70/S6K was activated significantly
n the hearts of infarcted animals, whereas treatment with
AD completely suppressed infarct-related p70/S6K acti-
ation. Activation of p70/S6K is associated with enhanced
rotein synthesis, which leads to myocardial hypertrophy
27–29). Rapamycin inhibits the p70/S6K effects as well as
yocardial hypertrophy in several animal models (8,10). In
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Figure 9 Long-Term Effects of RAD Treatment
The RAD treatment (starting on day 1 after MI) for 28 days led to sustained
improvement of LV function 3 months after MI (squares, solid lines), whereas
vehicle-treated animals display a progressive deterioration of LV ejection frac-
tion (triangles, dashed lines). Data from serial echocardiography in the same
animals are depicted. #p  0.05 versus vehicle. Abbreviations as in Figure 1.ontrast, deletion of ribosomal S6K1 and S6K2 does not Nlter the myocardial growth response of physiological or
athological stimuli, indicating that these kinases do not
eem to be mandatory for the development of cardiac
ypertrophy (27). However, this model has not been tested
n MI. Even if activation of p70/S6K seems to be a critical
actor for the development of cardiac hypertrophy in re-
ponse to MI, other pathways play a role in mediating the
ffect of mTOR inhibitors. Another downstream target of
TOR, 4E-BP1, an inhibitor of protein synthesis—which
s inactivated by mTOR—also modulates this response.
hosphorylation of 4E-BP1 is known to accelerate the
elease of eIF4E, allowing increased formation of the eIF4F
ranslation factor complexes (30). As noted in the preceding
ext, 4E-BP1-phosphorylation is reduced in RAD-treated
nimals, thereby dis-inhibiting its anti-growth properties.
bviously, these effects that are modulated by RAD can
rotect the heart from adverse remodeling effects.
Importantly, the physiological response to cellular stress
nvolves down-regulation of mTOR (31). In addition it has
een demonstrated that autophagy as an energy-recovering
rocess of protein degradation is associated with mTOR
nhibition in the context of myocardial ischemia (32).
p-regulation of autophagy acts as a protective mechanism
n the failing heart (33). These findings are consistent with
he inhibition of mTOR. Because myocardial blood flow is
ermanently discontinued in the central region of the infarct
one due to ligation of the corresponding coronary artery, it
s obvious that reduction of infarct size must be the result of
specific process in the border zone. The results of this
tudy demonstrate increased autophagy in the critical border
one upon mTOR inhibition. Moreover, a relevant down-
egulation of the ubiquitin proteasome system was observed.
uch a counter-regulation was demonstrated previously in
nother context (34). These results underline that mTOR
nhibition after MI mimics a conserved process for survival
f mammalian cells. Iwai-Kanai et al. (15) have demon-
trated that the mTOR inhibitor rapamycin increases auto-
hagosome formation, in line with the results from this
tudy. Concomitant with proteasome inhibition, NFB
ctivity was reduced in the border zone of the infarct in
AD-treated animals, and macrophage invasion was re-
uced. Palombella et al. (35) previously demonstrated that
he activity of the ubiquitin proteasome system is required
or activation of NFB. Also, in the heart, proteasome
nhibition blocks activation of NFB after myocardial isch-
mia (36). Inhibition of NFB activity by the mTOR
nhibitors rapamycin as well as RAD has also been found in
ther cell types (37,38). It is well-known that inflammation
s an important factor in myocardial remodeling spreading
f the infarction zone (39). Reduced MI size in mice after in
ivo transfection of cis element decoy against NFB has
reviously been shown (22). Frantz et al. (40) demonstrated
hat the deletion of the p50 subunit of NFB leads to
educed infarct size in mice. In addition, Li et al. (41)
emonstrated that overexpression of A20, which inhibits
FB, reduces post-infarct remodeling. However, another
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December 15/22, 2009:2435–46 mTOR Inhibition in Myocardial Infarctiontudy showed that pharmacological inhibition of NFB
tarting 24 h after MI for 28 days did improve LV
emodeling and cardiac dysfunction but did not reduce
nfarct size (42). Therefore, inhibition of the NFB path-
ay might contribute to improving adverse LV remodeling,
ut it is not clear whether reduced inflammation is also a
ontributing factor for infarct size reduction after RAD
reatment.
onclusions and Clinical Perspective
espite the widespread use of therapeutics interfering with
he neurohumoral axis, the incidence of heart failure as the
nd-stage of LV remodeling and cardiac hypertrophy re-
ains high. The mTOR inhibitors are successfully used for
revention of restenosis. The results of this study provide
vidence that the mTOR inhibitor RAD can prevent LV
emodeling after MI.
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